PD-L1 t-haNK is a natural killing cell-based immuno-oncology therapy which includes Chimeric Antigen Receptor (CAR) based on PD-L1 NantKwest, leading company in clinical-stage immunotherapy that develops activated natural killer cells (NK)....

E-commerce giant Amazon recently announced the launch of Amazon Professional Beauty Store, intended to sell beauty products used by licensed stylists, beauticians & barbers. Followed by the announcement, shares of many specialized beaut....

Parexel stands as a pioneer in the delivery and development of a wide range of FSP, with full and flexible clinical development services Parexel, a leading global provider of biopharmaceutical services and innovative therapies, recently a....

The agreement is strategically important for Delta to expand outside the U.S. market Delta, a major American Airline, recently announced that it has acquired a 4.3% stake in Hanjin Kal Corp., the parent company of Korean Air Lines Co Ltd.,....

Within forty days of closure of the acquisition, UnitedHealth Group would divest DaVita Medical Group’s healthcare provider in Las Vegas UnitedHealth Group has reportedly been granted approval by the Federal Trade Commission for its ....

RP-A501 gene therapy can make a significant difference in patients who are suffering from Monogenic Heart Failure Syndrome Rocket Pharmaceuticals Inc, a multi-platform clinical-stage gene therapy company based in the U.S., recently announc....

BioNTech SE, the largest privately held biopharmaceutical company in Europe, recently announced initiation of first-in-human study of DuoBody-PD-L1x4-1BB for the treatment of solid tumors, cite sources. For the record, BioNTech SE is a cli....

Virginia-based Peraton, a defense and intelligence contractor owned by private equity firm Veritas Capital, reportedly announced that it has signed a definitive agreement to acquire Solers Inc., a leading provider of software development an....

A clinical-stage immune-oncology company, Forty Seven, Inc., that works to develop therapies targeting cancer immune evasion pathways, has revealed clinical data from Phase 1b/2. The company is evaluating a new drug combination of Recombina....

Progenics Pharmaceuticals, Inc., a biopharmaceutical company, has recently announced that its first patient has been dosed for treatment of Metastatic Prostate cancer, in a phase 2 clinical study of 1095 radiotherapy. The clinical study eva....